Protalix Biotherapeutics, Inc. (NYSE: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company's proprietary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE